Great news! CDR-Life Inc. expands its innovative cancer therapy portfolio with the addition of two highly tumor-targeted T cell engagers (TCE): - CDR813: A powerhouse T cell engager targeting PRAME in HLA-A*02:01 patients. PRAME is a clinically validated pan-cancer target expressed in a broad set of tumors including non-small cell lung cancer, endometrial cancer, melanoma and ovarian cancer but not in normal tissue. This bi-valent, bi-specific antibody shows unparalleled potency and precision. - CDR505: Breaking new ground with a T cell engager for KK-LC-1 in HLA-A01 patients. This expands treatment possibilities beyond the common HLA-A02 focus to benefit a large patient population with high unmet need. These additions strengthen CDR-Life's mission to develop targeted cancer therapies for broader patient populations. Read more: https://bit.ly/4bldGNA
Congrats on the pipeline expansion, Christian!
Well done Stephanie and CDR-Life!!!
Head of R&D for LC-MS and Workflows at Biognosys
2moCongratulations, excellent work that you are doing! Looking forward to the progress of the therapies.